

Special Issue

Tumor Immunotherapy

Message from the Guest Editor

Immunotherapy has emerged as the next-generation frontier in cancer treatments, leading to relevant success in diverse cancer types, such as melanoma and lung cancer. Therefore, in this successful scenario, there is still an “unsuccessful” window for some cancer types. Potential topics for this Issue include, but are not limited to, the following:

- The tumor (immune)-microenvironment as a target for immunotherapy;
- Immune cell polarization and immunotherapy;
- Immune cell angiogenic switch and immunotherapy;
- Molecular pathways in immunotherapy;
- Strategies to re-educate immune cells in cancers;
- Combination therapies acting on the immune system in cancer;
- Delivering strategies in immunotherapy;
- Nanotechnologies in immunotherapy;
- Phytochemicals endowed with immunostimulatory actions for immunotherapy approaches, including vaccines;
- Marine drugs endowed with immunostimulatory actions for immunotherapy approaches, including vaccines.

Guest Editor

Dr. Antonino Bruno

1. Laboratory of Immunology and General Pathology, University of Insubria, Varese, Italy
2. Laboratory of Innate Immunity, IRCCS MultiMedica, Milan, Italy

Deadline for manuscript submissions

closed (31 October 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/51978

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).